Dr. Winter on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

Jane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Northwestern University, discusses the promise of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies.

It is too early to determine benefit of CAR T-cell therapy in follicular lymphoma, says Winter, with responses ranging from 40% to 50%. Although, there may be promise in combining other agents or altering the technique.

A large benefit has been seen in other hematologic malignancies such as diffuse large B-cell lymphoma, states Winter.